[CAS NO. 79-14-1] Glycolic acid
PRODUCTS SPECIFICATIONS [79-14-1]
DESCRIPTION [79-14-1]
Overview
| MDL | MFCD00004312 |
|---|---|
| Molecular Weight | 76.05 |
| Molecular Formula | C2H4O3 |
| SMILES | O=C(O)CO |
Summary
Glycolic acid is an inhibitor of tyrosinase , suppressing melanin formation and lead to a lightening of skin colour.
IC50 & Target
|
Microbial Metabolite |
Human Endogenous Metabolite |
In Vitro
Different concentrations of Glycolic acid (GA) or LA (300 and 500 mg/mL) are tested on the growth of mouse and human melanoma cells. Both types of cells grow well, even in the presence of 300 mg/mL of each chemical for 5 days. However, 500 mg/mL Glycolic acid inhibits the cell growth of mouse melanoma cells (41%) and humanmelanoma cells (27%), and 500 mg/mL of LA inhibits the growth of mouse melanoma cells (36%) [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT05362500 | Combined Military Hospital Abbottabad |
Melasma
|
June 1, 2021 | Phase 1 |
| NCT01976286 | Northwestern University |
Melanosis
|
January 2015 | Not Applicable |
| NCT05600075 | Zagazig University |
Acne Scars - Mixed Atrophic and Hypertrophic
|
November 1, 2022 | Not Applicable |
| NCT02126657 | National University Hospital, Singapore |
Acne Scars
|
May 2014 | Phase 2 |
| NCT01976273 | Northwestern University |
Melanosis
|
October 2013 | Not Applicable |
| NCT03153852 | Assiut University |
Melasma
|
March 15, 2018 | Phase 4 |
| NCT02126644 | National University Hospital, Singapore |
Photoaging
|
May 2014 | Phase 2 |
| NCT05471947 | Main Line Center for Laser Surgery |
Photoaging|Lentigo
|
September 1, 2022 | Phase 4 |
| NCT01289171 | University of Pennsylvania|NeoStrata Company, Inc.|Penn Center for AIDS Research (CFAR) |
Flat Warts (Diagnosis)|HIV Infections
|
January 2009 | Not Applicable |
| NCT00472966 | Galderma R&D |
Melasma
|
November 2006 | Phase 4 |
| NCT02812719 | Boston Medical Center |
Melasma
|
July 2018 | Early Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
H 2 O : 100 mg/mL ( 1314.92 mM ; Need ultrasonic)
DMSO : ≥ 100 mg/mL ( 1314.92 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 13.1492 mL | 65.7462 mL | 131.4924 mL |
| 5 mM | 2.6298 mL | 13.1492 mL | 26.2985 mL |
| 10 mM | 1.3149 mL | 6.5746 mL | 13.1492 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (1314.92 mM); Clear solution; Need ultrasonic
-
2.
-
3.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (32.87 mM); Clear solution
-
4.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (32.87 mM); Clear solution
Synonyms